Community/Retail

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Average total drug spending per hospital admission increased by 18.5% between FY2015 and FY2017.

US citizens are increasingly traveling to international destinations, with Americans making 38 million visits abroad in 2017. Fortunately, pharmacists are well-placed to assist patients in their travel health needs.

Officials with the FDA today approved the first generic version of vigabatrin 500-mg tablets, which is also sold under the brand name Sabril, a medication used to treat complex partial seizures.

This interoperable standard created to exchange information across the health care spectrum is gaining traction across the country.

Measles outbreaks are on the rise globally, and it is considered a public health crisis.

Approximately 94% of widely-used brand-name drugs on the market between 2005 and 2017 more than doubled in price during that time.

CVS Caremark has requested that Walmart continue to fill prescriptions as an in-network participating pharmacy through April 30, 2019.

Meet our #ThankAPharmacist Twitter contest winner, Dr. Lee Golden.

The FDA has approved Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) use to include repeat vaccination to help protect against tetanus, diphtheria and pertussis.

Pharmacists are encouraged to discuss vaccination and prevention options with patients.

Researchers at Kaiser Permanente Washington conducted a qualitative pilot study to understand the experiences and decision-making women face as they contemplate the use of antinausea medications during pregnancy.

In this video, Ryan Forrey, PharmD, MS, FASHP is the Senior Manager of Market Development for Hazardous Drugs at BD, discusses USP 800 and surface contamination monitoring.

The Pharmacy Times Salary and Job Satisfaction Survey shows that workload, management, and work/life balance were the 3 top drivers of dissatisfaction.

Tomorrow, pharmacists will be in the spotlight. It is also an opportunity for them to express pride in their work and share aspects of the job that keep them motivated.

Glucagon-like peptide-1 receptor agonists have been gaining popularity to treat diabetes. Does this one provide advantages over competitors?

In response to a growing demand for personalized medicine, the Midwestern University Chicago College of Pharmacy earlier this week announced the establishment of a Pharmacometrics Center of Excellence on the school’s Downers Grove Campus.

This selection of videos includes interviews by Pharmacy Times with key pharmacy professionals along with informative material produced by other educational entities on health conditions of interest to pharmacists.

On National Pharmacist Day, share your #APharmacistIs story on social media.

USP General Chapter , which was published by the United States Pharmacopeial Convention and updated most recently in December 2017, sets forth guidelines for the handling of hazardous drugs in the health care setting with the goal of promoting safety for patients and health care workers.

Patients receiving anticoagulation that need to have an invasive procedure performed may require a temporary interruption in their anticoagulation therapy to limit bleed risk.

Using a drug that increases GABA synthesis and possibly escalates intraneuronal dopamine in a population that is more likely to have behavior health concerns may prove to be an unsafe option.

An FDA-approved mobile application for adults with opioid use disorder (OUD) is now available by prescription. Pear Therapeutics’ reSET-O app aims to increase retention for adults who are in outpatient treatment programs.

A newly study published study aimed to distinguish between uninfected cells and latently infected cells, with hopes that eradicating the latent reservoirs could lead to a cure for the disease.

Sun Pharmaceutical Industries, Inc. (SPI) is voluntarily recalling 3 lots of 10 mg vecuronium bromide for injection and 1 lot of 20 mg vecuronium bromide for injection to the hospital level.

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Systems now available at a reduced list price of $5,850.

Health care costs in the US represent nearly 20% of the GDP.